C4X this morning announced their full year results and the video provides an investor relations overview from Clive Dix. C4X are a growth stock on London's AIM Stock Exchange, using the ticker LON:C4XD. C4X saw turnover grow to over £10m from £143,000 the previous year, and this was largely driven by a deal with Indivior (LON:INDV). The deal with Indivior provides a £10million upfront payment to C4X, with potential for a further £284 million in future royalties - this is dependant on milestones being met. The partnership is for their Orexin-1 antagonist programme, which targets addiction.